




Development of CD19-Targeting CAR-X Combination Therapy Candidates for Solid Tumor

artiCure
[a:rti]Cure

ONCOLOGY Candidate

Product Type	Gene & Nucleic acids
Indication	Incurable neoplasms (TNBC etc.)
Target	Proliferating tumor cells
MoA(Mechanism of Action)	Tagging: Universal Target Generation  • sRRV tumor-selective infection, CD19 gene transduction and surface expression, Increase in CD19 expression area and density due to intra-tumoral proliferation. Modulation: TME Reprogramming  • Enzyme-Prodrug (5-FC→5-FU) Conversion, Toxicity spread to uninfected cells (Debulking & Bystander), Immune arousal and TME alleviation. Immune Attack: Selective Immune Attack  • Selective killing, infiltration, persistence enhancement by anti-CD19 CAR-T/NK/MG, Immune Amplification Loop.
Competitiveness	Converts immunologically “cold” solid tumors into CAR-responsive tumors through tumor-selective CD19 tagging and local TME remodeling. Enables combination with existing CAR, ADC, and ICI therapies using a scalable oncospreading platform.
Development Stage	Candidate
Route of Administration	Intra-tumoral (systemic injection: under developing)

Any unauthorized distribution or reproduction of this material is strictly prohibited.